Although most of these BTH occurrences were likely pharmacodynamic (PD) due to a complement amplifying condition, i.e., a viral infection, rather than pharmacokinetic (PK) due to subtherapeutic complement inhibition, we did not have complete data on drug levels, C5 levels, or CH50 to differentiate between PD versus PK BTH. Here, C5 is linked to viral infectious disease.